Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.150
+0.040 (3.60%)
At close: Sep 5, 2025, 4:00 PM
1.160
+0.010 (0.87%)
After-hours: Sep 5, 2025, 7:37 PM EDT
Allogene Therapeutics Stock Forecast
ALLO's stock price has decreased by -55.43% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 8 analysts that cover Allogene Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $8.88, which forecasts a 672.17% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $14.
Price Target: $8.88 (+672.17%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2025.
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 6 | 6 | 6 | 4 | 4 |
| Hold | 1 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 4, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 4, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +247.83% | May 15, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $14 → $10 | Strong Buy | Maintains | $14 → $10 | +769.57% | May 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $7 | Buy | Maintains | $9 → $7 | +508.70% | May 14, 2025 |
Financial Forecast
Revenue This Year
11.33K
from 22.00K
Decreased by -48.49%
Revenue Next Year
22.66K
from 11.33K
Increased by 100.00%
EPS This Year
-1.01
from -1.32
EPS Next Year
-0.94
from -1.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105,000 | 105,000 | |||
| Avg | 11,332 | 22,664 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 377.3% | 826.6% | |||
| Avg | -48.5% | 100.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.92 | -0.58 | |||
| Avg | -1.01 | -0.94 | |||
| Low | -1.18 | -1.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.